Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families.

TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.

Clinical Trials

Life Sciences

Translational Drug Development (TD2)

Stephen Gately

Jennifer Vergara

Kristen Dempsey

Shawnna Rustenbeck

Alan Miller M.D.

Susan Night

The Leadership Team at Translational Drug Development (TD2) guides the strategic direction and overall vision of the organization. Comprising key executives such as the CEO, Chief Medical Officer, and Vice Presidents of various operational sectors, this team is responsible for driving business growth, fostering innovation in oncology research, and ensuring the effective execution of clinical strategies. Through collaborative decision-making and leveraging industry expertise, they aim to enhance the drug development process, ultimately improving outcomes for cancer patients.

Leadership Team

Clinical Data Management

Data Management Team

Leadership Team

About

Team members

Other teams at Translational Drug Development (TD2)

Clinical Data Management

Data Management Team